Search clinical trials for: Oral Naltrexone (O-NTX)

Total 173 results

NYU Langone Health

Completed

Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care (X-ON)

Alcohol Dependence

United States
Boston University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Alcohol Disorder hOsPital Treatment Trial (ADOPT)

Alcohol Dependence | Alcohol Use Disorder | Heavy Drinking

United States
San Diego State University

Recruiting

Understanding How Opioids Affect the Experiential and Neural Signatures of Social Experiences

Placebo | Naltrexone

United States
Oscotec Inc.

Completed

Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia

United States, Greece, Korea, Republic of, Poland, Spain
Yale University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Not yet recruiting

Emergency Department-Initiated Medications for Alcohol Use Disorder

Alcohol Use Disorder

United States
University of Pennsylvania
National Institute on Drug Abuse (NIDA); St. Petersburg State Pavlov Medical...

Completed

Addiction Treatment in Russia: Oral vs. Naltrexone Implant

Opioid-Related Disorders | Heroin Dependence

United States, Russian Federation
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence

Opioid Dependence

United States
University of California, Los Angeles
Alkermes, Inc.

Completed

Injectable Pharmacotherapy for Opioid Use Disorders (IPOD) (IPOD)

Opioid Use Disorders

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Improved Strategies for Outpatient Opioid Detoxification

Opioid Dependence

United States
Alkermes, Inc.

Completed

ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids

Opiate Dependence
Alkermes, Inc.

Terminated

ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997])

Alcoholism | Opiate Dependence
GlaxoSmithKline

Completed

To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers

Alcoholism

United Kingdom
University of Oslo
Norwegian Institute of Public Health; Oslo University Hospital; The Research... and other collaborators

Completed

Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway (NTX-SBX)

Opioid Dependence

Norway
State University of New York - Upstate Medical...
Cephalon

Completed

Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI) (vivitrol)

Alcohol Dependence | Schizophrenia | Schizoaffective Disorders | Bipolar Disorders

United States
University of Colorado, Denver

Withdrawn

In Hospital IM Naltrexone: A Pilot Study (IM-NTX)

Alcohol Use Disorder
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone (Depot-BNT)

Heroin Dependence | Opiate Dependence

United States
Centrexion Therapeutics

Completed

Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN

Painful Diabetic Neuropathy

United States
US Department of Veterans Affairs

Terminated

Pilot Study of Depot NTX in Homeless Veterans

Alcohol Dependence

United States
Romark Laboratories L.C.

Completed

Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B

Chronic Hepatitis B

Singapore
NYU Langone Health
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users

Alcohol Dependence | Alcohol Use Disorder

United States
University of Texas Southwestern Medical Center
National Institute on Drug Abuse (NIDA)

Recruiting

Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2) (CURB-2)

Cocaine Use Disorder

United States
NYU Langone Health
National Institute on Drug Abuse (NIDA); University of California, Los Angeles and other collaborators

Completed

Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry (XOR)

Opioid-Related Disorders | Heroin Dependence

United States
Fulcrum Therapeutics

Recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058

Sickle Cell Disease | Sickle Cell Anemia

United States
Alkermes, Inc.

Completed

ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)

Alcoholism
Duke University
Alkermes, Inc.; Laura and John Arnold Foundation; FHR (Fellowship Health Resources... and other collaborators

Completed

Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings (DC)

Opioid-Related Disorders

United States
Marta Peciña, MD PhD
Brain & Behavior Research Foundation

Completed

Study of Naltrexone-Induced Blockade of Antidepressant Effects (SONRISA2)

Depression | Major Depressive Disorder

United States
Friends Research Institute, Inc.
National Institute on Drug Abuse (NIDA)

Recruiting

Long-acting Naltrexone for Pre-release Prisoners

Opiate Addiction

United States
Lifespan
The Miriam Hospital; University of Rhode Island

Active, not recruiting

Medication Maintenance Therapy in Community Pharmacy Settings (MATPharm)

Opioid-use Disorder

United States
University of Pennsylvania
National Institute on Drug Abuse (NIDA)

Completed

Adherence to HIV Therapy in Heroin Addicts: Oral vs XR-NTX

HIV Infections | HIV | Substance Abuse

Russian Federation
Friends Research Institute, Inc.

Recruiting

Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail

Opioid-use Disorder

United States
Minia University

Completed

The Use of Naltrexone Hydrochloride to Promote Healing in Patients With Resistant Non-infectious Corneal Ulcer

Cornea Ulcer

Egypt
Texas Tech University
Texas Tech University Health Science Center

Recruiting

Naltrexone for Prolonged Grief Disorder (NPGD)

Placebo | Naltrexone HCl 50 MG Oral Tablet

United States
Fred Hutchinson Cancer Center
Yale University; Asociación Civil Impacta Salud y Educación, Peru

Completed

Naltrexone for Medication Compliance Among HIV-infected Men With Alcohol Use Disorder

HIV | Alcohol Use Disorder

Peru
Icahn School of Medicine at Mount Sinai

Completed

ED Initiated Oral Naltrexone for AUD

Alcohol Use Disorder

United States
NorthShore University HealthSystem

Completed

IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone

Interstitial Cystitis | Painful Bladder Syndrome | Bladder Pain Syndrome | Low Dose Naltrexone | Low-dose Naltrexone | Naltrexone

United States
Weill Medical College of Cornell University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Terminated

Naltrexone Treatment for Prolonged Grief Disorder (PGD) (PGD)

Prolonged Grief Disorder

United States
Naurex, Inc, an affiliate of Allergan plc

Completed

Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers (NRX-1074)

Major Depressive Disorder

United States
University of Pennsylvania
Alkermes, Inc.

Recruiting

Naltrexone in AUD Reward Drinkers

Alcoholism | Alcohol Use Disorder

United States
University of California, San Francisco
National Institute on Drug Abuse (NIDA)

Completed

Intermittent Naltrexone Among Polysubstance Users (Project iN)

Methamphetamine | Alcohol

United States
Odense University Hospital
University of Southern Denmark; University Hospital Bispebjerg and Frederiksberg

Completed

Fibromyalgia and Naltrexone: The FINAL Study (FINAL)

Fibromyalgia

Denmark
Scilex Pharmaceuticals, Inc.

Completed

Pharmacokinetics of SP-104

Healthy

New Zealand
Yale University
National Institute on Drug Abuse (NIDA); St. Petersburg State Pavlov Medical...

Completed

Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia

Opiate Dependence

Russian Federation
Scilex Pharmaceuticals, Inc.

Completed

Study to Evaluate the Safety of SP-104

Healthy Volunteers

New Zealand
Antares Pharma Inc.

Completed

Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device

Rheumatoid Arthritis (RA)

United States
Aptinyx
CogState Ltd.; Worldwide Clinical Trials

Active, not recruiting

NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)

Parkinson Disease | Mild Cognitive Impairment | Lewy Body Disease | Mild Dementia

United States
Aptinyx
inVentiv Health Clinical

Completed

Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia

Fibromyalgia

United States
Aptinyx
Massachusetts General Hospital; Premier Research Group plc

Completed

Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

Post-Traumatic Stress Disorder

United States
Bausch Health Americas, Inc.

Completed

Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose

Healthy Subjects

United States
NYU Langone Health
Harvard Medical School (HMS and HSDM); National Institute on Drug Abuse (NIDA) and other collaborators

Recruiting

Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Opioid Use Disorder (OUD)

United States
New York State Psychiatric Institute

Terminated

Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol

Opioid-use Disorder

United States

Search clinical trials for: Oral Naltrexone (O-NTX)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations